The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Lyell Immunopharma Inc’s stock clocked out at $0.66, down -6.95% from its previous closing price of $0.71. In other words, the price has decreased by -$6.95 from its previous closing price. On the day, 0.66 million shares were traded.
Ratios:
To gain a deeper understanding of LYEL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.43 and its Current Ratio is at 13.43. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on October 30, 2024, Downgraded its rating to Underperform and sets its target price to $1 from $6 previously.
On June 27, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $1.
JP Morgan Downgraded its Overweight to Neutral on August 28, 2023, whereas the target price for the stock was revised from $15 to $5.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3220.62 while its Price-to-Book (P/B) ratio in mrq is 0.32.
Stock Price History:
Over the past 52 weeks, LYEL has reached a high of $3.26, while it has fallen to a 52-week low of $0.51. The 50-Day Moving Average of the stock is 6.88%, while the 200-Day Moving Average is calculated to be -48.90%.
Shares Statistics:
A total of 256.56M shares are outstanding, with a floating share count of 124.31M. Insiders hold about 57.45% of the company’s shares, while institutions hold 22.73% stake in the company.
